IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
WHO2007 grading of diffuse gliomas in adults is well-established. However, IDH mutations make classification of gliomas according to the WHO2007 edition controversial. Here, we characterized IDH-1R132H mut status in a cohort of 670 adult patients with different WHO2007 grades of diffuse glioma. Patient characteristics, clinical data and prognoses were obtained from medical records. Patients with IDH-1R132H mut were younger and had better clinical outcomes than those without mutations. Differences in age among patients with astrocytomas of different WHO2007 grades were eliminated after patients were grouped based on IDH-1R132H status. IDH-1R132H mut was present more often in patients with lower Ki-67 and MGMT protein levels and higher mutant p53 levels. Ki-67 was also strongly associated with WHO2007 grade independently of IDH-1R132H mut status. Moreover, patients with Ki-67<30 survived longer than those with Ki-67≥30, regardless of IDH-1R132H mut status. Patients in the IDH-1R132H mut group with lower MGMT protein levels also had better clinical outcomes than those in other groups. Our results indicate that to better treat gliomas, IDH mutation status should be included when determining WHO2007 grade in glioma patients.
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Peng-Fei
PF
Wang
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Ning
N
Liu
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Hong-Wang
HW
Song
Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Kun
K
Yao
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.|Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Beijing Neurosurgical Institute, Beijing, China.|Beijing Institute for Brain Disorders, Beijing, China.
Tao
T
Jiang
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Shou-Wei
SW
Li
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Chang-Xiang
CX
Yan
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001932:Brain Neoplasms / Q000145:classification / Q000235:genetics* / Q000378:metabolism; D015331:Cohort Studies; D005260:Female; D005910:Glioma / Q000145:classification / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics* / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D060787:Neoplasm Grading; D011379:Prognosis; D055815:Young Adult
D014408:Biomarkers, Tumor; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human
IDH-1R132H mutation; Ki-67; gliomas; molecular pathology; prognosis